8-K
Schrodinger, Inc. (SDGR)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2021
Schrödinger, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 95-4284541 | |
|---|---|---|
| (State or other jurisdiction of<br><br><br>incorporation or organization) | 001-39206<br><br><br>(Commission File Number) | (I.R.S. Employer<br>Identification No.) |
| 120 West 45th Street, 17th Floor<br><br><br>New York, NY | 10036 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212) 295-5800
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, par value $0.01 per share | SDGR | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
|---|
On March 4, 2021, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits:
| Exhibit<br>Number | Description |
|---|---|
| 99.1 | Press release dated March 4, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Schrödinger, Inc. | ||
|---|---|---|
| Date: March 4, 2021 | By: | /s/ JOEL LEBOWITZ |
| Joel Lebowitz |
2
sdgr-ex991_6.htm
Exhibit 99.1
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021
Total revenue of $108.1 million in 2020, up 26 percent year-over-year
Software revenue of $92.5 million in 2020, up 39 percent year-over-year
Strong financial position enables continued investment in advancing the science underlying Schrödinger’s computational platform
Internal pipeline progressing, with plans to submit investigational new drug applications in 2022
Conference call today, Thursday, March 4, at 8:30 a.m. ET
New York, March 4, 2021 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided its financial outlook for 2021.
“2020 was a very strong year for Schrödinger across all aspects of our business. Software revenue increased substantially, and we expect continued growth in 2021. We believe this growth reflects the power of our physics-based platform to accelerate the discovery of new medicines and materials,” stated Ramy Farid, Ph.D., chief executive officer at Schrödinger.
“We finished 2020 in a strong financial position. Looking across multiple key indicators, we believe our underlying business is poised for continued growth this year,” said Joel Lebowitz, chief financial officer at Schrödinger. “Importantly, our balance sheet and growing revenue enable us to make strategic investments in both our computational platform and our internal pipeline to build for the future.”
Business Highlights
Delivered strong operating performance and strategic execution
| ● | Reported 28 percent total revenue growth in the fourth quarter of 2020, driven by continued uptake of Schrödinger’s core technologies including FEP+ and its enterprise solution, LiveDesign |
|---|---|
| ● | Entered into a strategic collaboration with Bristol Myers Squibb to discover, develop, and commercialize therapeutics in multiple disease areas. Under the terms of the agreement, Schrödinger received $55 million in an upfront payment and is eligible to receive up to $2.7 billion in preclinical, development, regulatory and sales-based milestone payments in addition to royalties on net sales of each product commercialized by Bristol Myers Squibb. |
| --- | --- |
| ● | Ended the fourth quarter of 2020 with cash, cash equivalents, restricted cash and marketable securities of $643.2 million, compared to $599.5 million at September 30, 2020 |
| --- | --- |
Progressed internal pipeline
| ● | Presented preclinical data on the company’s MALT1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting highlighting that its MALT1 inhibitors demonstrated anti-tumor activity alone and in combination with approved anti-cancer therapies in models of B-cell lymphoma |
|---|---|
| ● | Continued to advance multiple programs toward IND-enabling studies; subject to completion of the preclinical data packages, the company expects to submit up to three IND applications in 2022, with the first submission expected in the first half of next year |
| --- | --- |
| ● | Advanced discovery efforts to allow addition of new programs to the company’s internal pipeline in 2021 |
| --- | --- |
Advanced the science underlying Schrödinger’s computational platform
| ● | Expanded its collaboration with Google Cloud to further increase the speed and capacity of its computational platform, effectively tripling Schrödinger’s previous throughput under the collaboration |
|---|---|
| ● | Released a major update to Schrödinger’s proprietary force field, called OPLS4, which underlies Schrödinger’s most powerful molecular design technologies, such as FEP+, allowing for even greater accuracy of the computational predictions |
| --- | --- |
| ● | Published four scientific papers, including a publication describing how to improve outcomes for fragment linking, an important technique used in early drug discovery, to potentially enable the design of novel drug-like inhibitors for challenging targets |
| --- | --- |
Fourth Quarter 2020 Financial Results
| ● | Revenue was $33.0 million for the fourth quarter of 2020, an increase of 28 percent compared to the fourth quarter of 2019. |
|---|---|
| ● | Software revenue was $25.0 million for the fourth quarter of 2020, an increase of 42 percent compared to the fourth quarter in 2019. |
| --- | --- |
| ● | Drug discovery revenue was $8.1 million for the fourth quarter of 2020, compared to $8.3 million in the fourth quarter of 2019. Drug discovery revenue in the fourth quarter of 2020 included $1.0 million related to the $55 million up-front payment from the strategic agreement with Bristol Myers Squibb announced in November 2020. |
| --- | --- |
| ● | Gross profit was $19.0 million in the fourth quarter of 2020, an increase of 22 percent over the fourth quarter in 2019. Software gross margin was 77 percent in the fourth quarter, compared to 79 percent for the same period in the prior year. |
| --- | --- |
| ● | Operating expenses for the fourth quarter of 2020 were $35.6 million, compared to $23.4 million in fourth quarter of 2019. |
| --- | --- |
| ● | Other income, which included gains on equity investments, changes in fair value of such investments and interest income, was $5.2 million in the fourth quarter of 2020 compared to $0.7 million for the fourth quarter of 2019. Other income for the fourth quarter of 2020 included a $5.2 million non-cash gain from Schrödinger’s equity stake in Morphic Therapeutic. |
| --- | --- |
| ● | Net loss, after adjusting for non-controlling interests, was $11.1 million for the fourth quarter of 2020, compared to a net loss of $6.8 million in the fourth quarter of 2019. |
| --- | --- |
Full Year 2020 Financial Results
| ● | Total revenue was $108.1 million for 2020, an increase of 26 percent compared to 2019. |
|---|---|
| ● | Software revenue was $92.5 million for 2020, an increase of 39 percent over 2019. |
| --- | --- |
| ● | Drug discovery revenue was $15.6 million for 2020, compared to $18.8 million in 2019. |
| --- | --- |
| ● | Gross profit was $63.5 million for 2020, an increase of 29 percent over 2019. Software gross margin was 81 percent for the year, compared to 80 percent in 2019. |
| --- | --- |
| ● | Operating expenses for 2020 were $124.4 million, compared to $87.8 million in 2019. |
| --- | --- |
| ● | Other income, which included gains on equity investments, changes in fair value of such investments and interest income was $34.6 million in 2020 compared to $12.7 million in 2019. Other income for 2020 included a $17.6 million non-cash gain from Schrödinger’s equity stake in Relay Therapeutics and a $13.7 million non-cash gain from the company’s equity stake in Morphic Therapeutic, partially offset by a loss of $3.0 million related to the company’s equity stake in Nimbus Therapeutics. |
| --- | --- |
| ● | Net loss, after adjusting for non-controlling interests, was $24.5 million for 2020, compared to a net loss of $24.6 million in 2019. |
| --- | --- |
| ● | At December 31, 2020, Schrödinger had cash, cash equivalents, restricted cash and marketable securities of $643.2 million. |
| --- | --- |
Full Year 2020 Key Performance Indicators
| ● | Total annual contract value (ACV) was $92.1 million in 2020, up 22 percent over 2019 |
|---|---|
| ● | Number of customers over $1 million in ACV was 16 in 2020, up from 10 in 2019 |
| --- | --- |
| ● | Number of customers over $100,000 in ACV was 153 in 2020, up from 131 in 2019; customer retention in this cohort was 99 percent |
| --- | --- |
| ● | Number of Active Customers with ACV over $1,000 was 1,463, up from 1,266 in 2019 |
| --- | --- |
For additional information about our Key Performance Indicators, see “Operating Metrics” below.
Full-Year 2021 Revenue Outlook
As of March 4, 2021, Schrödinger expects total revenue to range from $124 million to $142 million, with software revenue expected to range from $102 million to $110 million, and drug discovery revenue expected to range from $22 million to $32 million for the fiscal year ended December 31, 2021.
Webcast and Conference Call Information
Schrödinger will host a conference call to discuss its third quarter financial results on Thursday, March 4, 2020, at 8:30 a.m. ET. The conference call can be accessed live by dialing (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and referring to conference ID 9686253. The webcast can also be accessed under “News & Events” in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. The archived webcast will be available on Schrödinger’s website following the event.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com and follow us on LinkedIn and Twitter.
Operating Metrics
To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States (“GAAP”), we also present certain other performance metrics, such as annual contract value and customer retention rate.
Annual Contract Value (ACV). We track the ACV for each of our customers. With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, we define ACV as the contract value billed during the applicable period. For contracts with a duration of more than one year that are billed upfront, ACV in each period represents the total billed contract value divided by the term. ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. ACV is not intended to be a replacement for, or forecast of, revenue.
Customer Retention for our customers with an ACV of over $100,000. We calculate year-over-year customer retention for our customers in this cohort by starting with the number of customers we had in the previous fiscal year. We then calculate how many of these customers were active customers in the current fiscal year. We then divide this number by the number of customers with an ACV over $100,000 we had in the previous fiscal year to arrive at the year-over-year customer retention rate for such customers.
Active Customers. We define an active customer as a customer that had an ACV of at least $1,000 in the fiscal year. We use $1,000 as a threshold for defining our active customers as this amount will generally exclude customers that only license our PyMOL software, which is our open-source molecular visualization system broadly available at low cost.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding our expectations about the speed and capacity of our computational platform, our outlook for the fiscal year ended December 31, 2021, our plans to continue to invest in research and our strategic plans to accelerate the growth of our software business and advance our collaborative and internal drug discovery programs, our ability to improve and advance the science underlying our platform, including through these use of new technologies, the timing of potential IND applications for our internal drug discovery programs, our ability to realize potential milestones, royalties or other payments under our collaborations, as well as our expectations related to the use of our cash, cash equivalents, and marketable securities. Statements including words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the demand for our software solutions, our ability to further develop our computational platform, our reliance upon third-party providers of cloud-based infrastructure to host our software solutions, our reliance upon our third-party drug discovery
collaborators, the uncertainties inherent in drug development and commercialization, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business and other risks detailed under the caption “Risk Factors” and elsewhere in our Securities and Exchange Commission filings and reports, including our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, as well as future filings and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
Contacts:
Jaren Irene Madden
Schrödinger, Inc.
617-286-6264
Stephanie Simon (media)
Ten Bridge Communications
617-581-9333
| Consolidated Statements of Operations | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except for share and per share amounts) | ||||||
| Year Ended December 31, | ||||||
| 2020 | 2019 | |||||
| Revenues: | ||||||
| Software products and services | $ | 92,530 | $ | 66,735 | ||
| Drug discovery | 15,565 | 18,808 | ||||
| Total revenues | 108,095 | 85,543 | ||||
| Cost of revenues: | ||||||
| Software products and services | 18,003 | 13,646 | ||||
| Drug discovery | 26,620 | 22,804 | ||||
| Total cost of revenues | 44,623 | 36,450 | ||||
| Gross profit | 63,472 | 49,093 | ||||
| Operating expenses: | ||||||
| Research and development | 64,695 | 39,404 | ||||
| Sales and marketing | 17,795 | 21,364 | ||||
| General and administrative | 41,898 | 27,040 | ||||
| Total operating expenses | 124,388 | 87,808 | ||||
| Loss from operations | (60,916 | ) | (38,715 | ) | ||
| Other income: | ||||||
| Gain on equity investments | 4,108 | 943 | ||||
| Change in fair value | 28,263 | 9,922 | ||||
| Interest income | 2,253 | 1,878 | ||||
| Total other income | 34,624 | 12,743 | ||||
| Loss before income taxes | (26,292 | ) | (25,972 | ) | ||
| Income tax expense (benefit) | 345 | (291 | ) | |||
| Net loss | (26,637 | ) | (25,681 | ) | ||
| Net loss attributable to noncontrolling interest | (2,174 | ) | (1,110 | ) | ||
| Net loss attributable to Schrödinger common and<br><br><br>limited common stockholders | $ | (24,463 | ) | $ | (24,571 | ) |
| Net loss per share attributable to Schrödinger<br><br><br>common and limited common stockholders, basic and diluted: | $ | (0.41 | ) | $ | (4.09 | ) |
| Weighted average shares used to compute net loss<br><br><br>per share attributable to Schrödinger common and<br><br><br>limited common stockholders, basic and diluted: | 60,024,658 | 6,004,500 | ||||
| Consolidated Balance Sheets | ||||||
| --- | --- | --- | --- | --- | --- | |
| (in thousands, except for share and per share amounts) | ||||||
| Assets | December 31, 2019 | |||||
| Current assets: | ||||||
| Cash and cash equivalents | 202,296 | $ | 25,986 | |||
| Restricted cash | 500 | 500 | ||||
| Marketable securities | 440,395 | 59,844 | ||||
| Accounts receivable, net of allowance for doubtful accounts of 60 and 50 | 31,423 | 18,676 | ||||
| Unbilled and other receivables | 3,955 | 7,062 | ||||
| Prepaid expenses | 4,409 | 6,468 | ||||
| Total current assets | 682,978 | 118,536 | ||||
| Property and equipment, net | 5,140 | 6,268 | ||||
| Equity investments | 45,664 | 15,366 | ||||
| Right of use assets | 10,129 | 12,762 | ||||
| Other assets | 2,352 | 2,338 | ||||
| Total assets | 746,263 | $ | 155,270 | |||
| Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit) | ||||||
| Current liabilities: | ||||||
| Accounts payable | 8,398 | $ | 3,524 | |||
| Accrued payroll, taxes, and benefits | 12,000 | 7,034 | ||||
| Deferred revenue | 45,403 | 25,054 | ||||
| Lease liabilities | 4,543 | 5,584 | ||||
| Other accrued liabilities | 2,861 | 3,824 | ||||
| Total current liabilities | 73,205 | 45,020 | ||||
| Deferred revenue, long-term | 41,164 | 2,205 | ||||
| Lease liabilities, long-term | 7,221 | 8,888 | ||||
| Other liabilities, long-term | 654 | 900 | ||||
| Total liabilities | 122,244 | 57,013 | ||||
| Commitments and contingencies | ||||||
| Convertible preferred stock: | ||||||
| Series E convertible preferred stock, 0.01 par value. Authorized zero and 77,150,132<br> shares; zero and 73,795,777 shares issued and outstanding at December 31, 2020 and<br> December 31, 2019, respectively | — | 109,270 | ||||
| Series D convertible preferred stock, 0.01 par value. Authorized zero and 39,540,611<br> shares; zero and 39,540,611 shares issued and outstanding at December 31, 2020 and<br> December 31, 2019, respectively | — | 22,000 | ||||
| Series C convertible preferred stock, 0.01 par value. Authorized zero and 47,242,235<br> shares; zero and 47,242,235 shares issued and outstanding at December 31, 2020 and<br> December 31, 2019, respectively | — | 19,844 | ||||
| Series B convertible preferred stock, 0.01 par value. Authorized zero and 29,468,101<br> shares; zero and 29,468,101 shares issued and outstanding at December 31, 2020 and<br> December 31, 2019, respectively | — | 9,840 | ||||
| Series A convertible preferred stock, 0.01 par value. Authorized zero and 134,704,785<br> shares; zero and 134,704,785 shares issued and outstanding at December 31, 2020 and<br> December 31, 2019, respectively | — | 30,626 | ||||
| Total convertible preferred stock | — | 191,580 | ||||
| Stockholders’ equity (deficit): | ||||||
| Common stock, 0.01 par value. Authorized 500,000,000 and 425,000,000 shares;<br> 60,713,534 and 6,121,821 shares issued and outstanding at December 31, 2020<br> and December 31, 2019, respectively | 607 | 61 | ||||
| Limited common stock, 0.01 par value. Authorized 100,000,000 and 146,199,885 shares;<br> 9,164,193 and zero shares issued and outstanding at December 31, 2020 and<br> December 31, 2019, respectively | 92 | — | ||||
| Additional paid-in capital | 752,558 | 11,655 | ||||
| Accumulated deficit | (129,559 | ) | (105,096 | ) | ||
| Accumulated other comprehensive income | 317 | 16 | ||||
| Total stockholders’ equity (deficit) of Schrödinger stockholders | 624,015 | (93,364 | ) | |||
| Noncontrolling interest | 4 | 41 | ||||
| Total stockholders’ equity (deficit) | 624,019 | (93,323 | ) | |||
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | 746,263 | $ | 155,270 |
All values are in US Dollars.
| Consolidated Statements of Cash Flows | ||||||
|---|---|---|---|---|---|---|
| (in thousands) | ||||||
| Year Ended December 31, | ||||||
| 2020 | 2019 | |||||
| Cash flows from operating activities: | ||||||
| Net loss | $ | (26,637 | ) | $ | (25,681 | ) |
| Adjustments to reconcile net loss to net cash provided by (used in) | ||||||
| operating activities: | ||||||
| Gain on equity investments | (4,108 | ) | (943 | ) | ||
| Noncash revenue from equity investments | (397 | ) | (186 | ) | ||
| Fair value adjustments | (28,263 | ) | (9,922 | ) | ||
| Depreciation | 3,658 | 3,640 | ||||
| Stock-based compensation | 10,545 | 2,193 | ||||
| Noncash research and development expenses | 2,137 | 1,051 | ||||
| Noncash investment accretion | 646 | (506 | ) | |||
| Decrease (increase) in assets: | ||||||
| Accounts receivable, net | (12,747 | ) | (5,038 | ) | ||
| Unbilled and other receivables | 3,468 | (1,556 | ) | |||
| Reduction in the carrying amount of right of use assets | 5,342 | 4,177 | ||||
| Prepaid expenses and other assets | 187 | 410 | ||||
| Increase (decrease) in liabilities: | ||||||
| Accounts payable | 4,882 | (294 | ) | |||
| Accrued payroll, taxes, and benefits | 4,966 | 2,948 | ||||
| Deferred revenue | 59,705 | 6,715 | ||||
| Lease liabilities | (5,417 | ) | (4,025 | ) | ||
| Other accrued liabilities | (1,210 | ) | 958 | |||
| Net cash provided by (used in) operating activities | 16,757 | (26,059 | ) | |||
| Cash flows from investing activities: | ||||||
| Purchases of property and equipment | (2,538 | ) | (1,836 | ) | ||
| Purchases of equity investments | (2,869 | ) | — | |||
| Distribution from equity investment | 4,582 | 943 | ||||
| Purchases of marketable securities | (519,668 | ) | (110,187 | ) | ||
| Proceeds from sale and maturity of marketable securities | 138,772 | 57,225 | ||||
| Net cash used in investing activities | (381,721 | ) | (53,855 | ) | ||
| Cash flows from financing activities: | ||||||
| Issuances of common stock upon initial public offering, net | 211,491 | — | ||||
| Issuances of common stock upon follow-on public offering, net | 325,600 | — | ||||
| Issuances of Series E preferred stock, net | — | 29,893 | ||||
| Issuances of common stock upon stock option exercise | 4,183 | 549 | ||||
| Contribution by noncontrolling interest | — | 100 | ||||
| Deferred offering costs | — | (1,858 | ) | |||
| Net cash provided by financing activities | 541,274 | 28,684 | ||||
| Net increase (decrease) in cash and cash equivalents and restricted cash | 176,310 | (51,230 | ) | |||
| Cash and cash equivalents and restricted cash, beginning of year | 26,486 | 77,716 | ||||
| Cash and cash equivalents and restricted cash, end of year | $ | 202,796 | $ | 26,486 | ||
| Supplemental disclosure of cash flow and noncash information | ||||||
| Cash paid for income taxes | $ | 381 | $ | 139 | ||
| Supplemental disclosure of non-cash investing and financing activities | ||||||
| Accrued deferred offering costs | — | 2,142 | ||||
| Purchases of property and equipment | 8 | 90 | ||||
| Acquisitions of right of use assets in exchange for lease obligations | 2,709 | 464 | ||||
| Right of use assets recognized on adoption | — | 16,475 | ||||
| Reclassification of deferred financing costs to additional paid-in capital | 1,858 | — |